BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
The Best Business visionaries Under 30 - 2You finally got a doctor's appointment. Here's how to get the most out of it
- 3Lebanon says Israeli strike killed 13 people near Palestinian refugee camp
- 4Instructions to Really Oversee Unsold SUVs in the Auto Business
- 5RFK Jr.'s diet guidelines emphasize red meat, full-fat dairy. How healthy are they?
- The Best 20 Photography Instagram Records to Follow
- Nordic people know how to beat the winter blues. Here's how to find light in the darkest months
- How much would you pay to meet a Real Housewife? At BravoCon, the limit does not exist.
- As world leaders enter climate talks, people in poverty have the most at stake
- Instructions to Clean and Really focus on Your Lab Precious stone
- From Specialist to Proficient Picture taker: Individual Triumphs
- A new mom skipped a routine appointment. An infected cut led to a devastating diagnosis
- Sally Rooney books may be withdrawn from UK sale over Palestine Action ban, court told
- Figure out How to Track the Establishment of New 5G Pinnacles
